No Data Yet
HUTCHMED (00013) secured acceptance and Priority Review from China's NMPA for its savolitinib New Drug Application for gastric cancer, supported by positive Phase II trial data.
Alvotech (NASDAQ: ALVO) launched a $100 million convertible bond offering to fund its biosimilar pipeline and global expansion. The move comes as the company reaffirms 2025 guidance and sets ambitious 2026 targets, despite acknowledging potential U.S. regulatory delays.